JP2013528376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528376A5 JP2013528376A5 JP2013510342A JP2013510342A JP2013528376A5 JP 2013528376 A5 JP2013528376 A5 JP 2013528376A5 JP 2013510342 A JP2013510342 A JP 2013510342A JP 2013510342 A JP2013510342 A JP 2013510342A JP 2013528376 A5 JP2013528376 A5 JP 2013528376A5
- Authority
- JP
- Japan
- Prior art keywords
- odc
- ornithine decarboxylase
- polyamine
- inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34504810P | 2010-05-14 | 2010-05-14 | |
| US61/345,048 | 2010-05-14 | ||
| PCT/US2011/036464 WO2011143579A2 (en) | 2010-05-14 | 2011-05-13 | Cancer prevention and treatment methods based on dietary polyamine content |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138684A Division JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528376A JP2013528376A (ja) | 2013-07-11 |
| JP2013528376A5 true JP2013528376A5 (https=) | 2014-07-03 |
| JP6083646B2 JP6083646B2 (ja) | 2017-02-22 |
Family
ID=44915003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510342A Expired - Fee Related JP6083646B2 (ja) | 2010-05-14 | 2011-05-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| JP2016138684A Pending JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138684A Pending JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130217743A1 (https=) |
| EP (1) | EP2568978B1 (https=) |
| JP (2) | JP6083646B2 (https=) |
| CA (1) | CA2799431A1 (https=) |
| WO (1) | WO2011143579A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| HUE040263T2 (hu) | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| WO2015195120A1 (en) * | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| CA2976106A1 (en) | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| MA43114A (fr) | 2015-10-30 | 2018-09-05 | Cancer Prevention Pharmaceuticals Inc | Formulation combinée à dose fixe d'éflornithine et sulindac |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| CN109069462A (zh) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| AU2022381070A1 (en) * | 2021-11-02 | 2024-06-13 | The Trustees Of Indiana University | Methods of treating patients having type 1 diabetes with eflornithine |
| WO2024105276A1 (en) * | 2022-11-20 | 2024-05-23 | Universität Zürich | Combination of polyamine pathway inhibitor drug and proline/arginine diet restriction |
| CN115976243A (zh) * | 2023-02-27 | 2023-04-18 | 贵州医科大学 | 口服阿司匹林及阿托伐他汀出现的肠道菌群标志物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2706255B1 (fr) * | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| CA2325080A1 (en) * | 1998-03-28 | 1999-10-07 | The Regents Of The University Of California | Dfmo and sulindac combination in cancer chemoprevention |
| EP1351675A2 (en) * | 2000-08-24 | 2003-10-15 | The Regents of the University of California | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| PT2430452E (pt) * | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
-
2011
- 2011-05-13 CA CA 2799431 patent/CA2799431A1/en not_active Abandoned
- 2011-05-13 US US13/697,984 patent/US20130217743A1/en not_active Abandoned
- 2011-05-13 EP EP11781359.2A patent/EP2568978B1/en not_active Not-in-force
- 2011-05-13 WO PCT/US2011/036464 patent/WO2011143579A2/en not_active Ceased
- 2011-05-13 JP JP2013510342A patent/JP6083646B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-13 JP JP2016138684A patent/JP2016224056A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528376A5 (https=) | ||
| Law | Cancer cachexia: Pathophysiology and association with cancer-related pain | |
| Li et al. | Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance | |
| Suganuma et al. | New cancer treatment strategy using combination of green tea catechins and anticancer drugs | |
| Marin et al. | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer | |
| JP2016224056A5 (https=) | ||
| Hoffe et al. | Cancer and age: general considerations | |
| Toledo et al. | A multifactorial anti‐cachectic approach for cancer cachexia in a rat model undergoing chemotherapy | |
| Takeuchi et al. | Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma | |
| Tschoep-Lechner et al. | Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer | |
| Meng et al. | Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence | |
| Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
| He et al. | Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder | |
| Murphy et al. | Inhibition of the renin–angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia | |
| Appel et al. | The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain | |
| JP2012526852A5 (https=) | ||
| Katz et al. | Epigenetic reprogramming in breast cancer: from new targets to new therapies | |
| Yu et al. | Si‐jun‐zi decoction treatment promotes the restoration of intestinal function after obstruction by regulating intestinal homeostasis | |
| Men et al. | Nogo‐B: A potential indicator for hepatic cirrhosis and regulator in hepatic stellate cell activation | |
| Seidensticker et al. | Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial | |
| Whittle et al. | Histone deacetylase inhibitors in cancer: What have we learned? | |
| Younes et al. | An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma | |
| Chang et al. | Increased use of multidisciplinary treatment modalities adds little to the outcome of rectal cancer treated by optimal total mesorectal excision | |
| Pilgrim et al. | The developing clinical problem of chemotherapy‐induced hepatic injury | |
| Welsh et al. | Urticarial vasculitis secondary to paroxetine |